Abstract
RNA viruses cause human diseases ranging from mild colds to deadly pandemics. Direct-acting, broad-spectrum, non-nucleoside antivirals have been characterized as impossible to develop because allosteric binding sites are poorly conserved. The HCV NS5B RNA-dependent RNA polymerase (RdRp) Thumb-1 allosteric site and its interaction with the HCV NS5B Λ1-loop governs an essential conformational change required for polymerase initiation. The only approved NS5B Thumb-1 inhibitor, beclabuvir, has been shown to be inactive against a broad panel of non-HCV viruses, including poliovirus, rhinovirus, coronavirus, coxsackievirus, influenzavirus, and HIV. A conserved, homologous allosteric site on RdRp that spans multiple viral families has not been reported. Here, we report GALILEO’s discovery that the Thumb-1 pocket, its associated Λ1-loop and their interaction are conserved between RNA viral families for the first time. The discovery is structurally validated through comparative analysis of Protein Data Bank (PDB)-deposited viral polymerases utilizing a method that allows independent, public validation. We further demonstrate that beclabuvir’s dependence on its indole C6 carbonyl to interact with the HCV-specific residue R503 restricts its activity to HCV. The discovery is biochemically validated with MDL-001, which does not contain a C6 carbonyl substituent. MDL-001 directly blocks viral RNA synthesis in isolated HCV and SARS-CoV-2 replication complexes and selects for the canonical Thumb-1 resistance mutation P495S in HCV NS5B. The discovery is validated at the cellular level through demonstration of MDL-001’s broad-spectrum, in vitro inhibition of both HCV and SARS-CoV-2. Preclinical proof of concept and development of MDL-001 in HCV, HBV, HDV, influenza, SARS-CoV-2, and RSV have been previously reported. These findings establish RdRp Thumb-1 as a conserved allosteric pocket and a druggable target for broad-spectrum direct-acting antiviral development.